SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State of other jurisdiction
(Address of principal executive offices and Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|ITEM 8.01|| |
On March 5, 2021, Ameren Corporation (“Ameren”) sold $450 million principal amount of its 1.75% Senior Notes due 2028 (the “Notes”). The Notes were offered pursuant to a Registration Statement on Form S-3 (File No. 333-249475), which became effective on October 14, 2020, and a Prospectus Supplement dated February 24, 2021, to a Prospectus dated October 14, 2020. Ameren received net offering proceeds of approximately $446.8 million, before expenses, upon closing of the transaction. Ameren intends to use the net offering proceeds for general corporate purposes, including to repay its short-term debt.
This Current Report on Form 8-K is being filed to report as exhibits certain documents in connection with the offering of the Notes.
|ITEM 9.01|| |
Financial Statements and Exhibits.
|1||Underwriting Agreement, dated February 24, 2021 between Ameren and the several underwriters named therein, for whom Barclays Capital Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and MUFG Securities Americas Inc. are acting as representatives.|
|4.1*||Indenture, dated as of December 1, 2001, from Ameren to The Bank of New York Mellon Trust Company, N.A., as successor trustee (“Ameren Indenture”) (Exhibit 4.5, File No. 333-81774).|
|4.2*||First Supplemental Indenture to Ameren Indenture dated as of May 19, 2008 (June 30, 2008 Form 10-Q, Exhibit 4.1, File No. 1-14756).|
|4.3||Company Order, dated March 5, 2021, establishing the Notes.|
|5.1||Opinion of Craig W. Stensland, Esq., Senior Corporate Counsel, Ameren Services Company, regarding the legality of the Notes (including consent).|
|5.2||Opinion of Morgan, Lewis & Bockius LLP, regarding the legality of the Notes (including consent)|
|104||Cover Page Interactive Data File (formatted as Inline XBRL)|
Incorporated by reference as indicated.
- 2 -
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|Name:||Michael L. Moehn|
|Title:||Executive Vice President and Chief Financial Officer|
Date: March 5, 2021